

Tanios Bekaii-Saab

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10009411/tanios-bekaii-saab-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212
papers

8,765
citations

46
h-index

89
g-index

225
ext. papers

10,925
ext. citations

6
avg, IF

5.86
L-index

#	Paper	IF	Citations
212	Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100156	3.6	5
211	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. <i>JAMA Network Open</i> , 2022 , 5, e2142046	10.4	1
210	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2022 , 5, e2149040	10.4	4
209	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e224304	10.4	4
208	Frontline therapy for advanced hepatocellular carcinoma: an update.. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 17562848221086126	4.7	1
207	Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 ,	4.5	1
206	Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. <i>JAMA Network Open</i> , 2021 , 4, e2134458	10.4	1
205	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
204	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021 , 26, 668-675	5.7	6
203	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021 , 26, 610-618	5.7	
202	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3641-3648	12.9	7
201	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021 , 41, 136-141	7.3	6
200	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 3337-3348	7.4	2
199	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data-Reply. <i>JAMA Oncology</i> , 2021 , 7, 941	13.4	
198	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. <i>European Journal of Cancer</i> , 2021 , 151, 14-24	7.5	4
197	Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 309-316	5.9	15
196	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. <i>Pancreatology</i> , 2021 , 21, 192-199	3.8	2

195	Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. <i>Cancers</i> , 2021 , 13,	6.6	15
194	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2021 , 1	4.3	8
193	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021 ,	13.4	47
192	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	18.8	80
191	Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. <i>Oncologist</i> , 2020 , 25, e1246-e1248	5.7	0
190	Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. <i>Chinese Clinical Oncology</i> , 2020 , 9, 6	2.3	6
189	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020 , 49, 193-200	2.6	10
188	Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. <i>EMBO Molecular Medicine</i> , 2020 , 12, e9910	12	11
187	A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. <i>Oncologist</i> , 2020 , 25, 203-207	5.7	5
186	Precision Medicine in Metastatic Colorectal Cancer Finding and Hitting the Right Targets. <i>Oncology & Hematology Review</i> , 2020 , 16, 36	0.1	
185	Systemic Treatment for Metastatic or Recurrent Disease 2020 , 275-287		
184	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020 , 132, 112-121	7.5	12
183	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020 , 73, 1109-1117	13.4	9
182	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020 , 10, 22087	4.9	6
181	The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, e194489	13.4	28
180	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020 , 20, 101-109	3.8	12
179	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2020 , 6, e204930	13.4	49
178	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920956862	5.4	6

177	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , 2020 , 123, 1377-1386	8.7	1
176	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. <i>Onc Immunology</i> , 2020 , 9, 1818437	7.2	7
175	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020 , 20, 1115-1122	3.8	6
174	The Role of Maintenance Therapy in Metastatic Colorectal Cancer-Reply. <i>JAMA Oncology</i> , 2020 , 6, 937-938	3.4	1
173	Improvements in Clinical Outcomes for -Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4435-4441	12.9	6
172	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3117-3125	12.9	4
171	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 782-794	9.7	113
170	Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2019 , 7,	4.8	19
169	Watch and Wait in Rectal Cancer: Who's In and Who's Out?. <i>Journal of Oncology Practice</i> , 2019 , 15, 133-134	3.4	0
168	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1015-1027	2.2	157
167	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3495-3507	12.9	21
166	Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2019 , 11,	6.6	13
165	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , 2019 , 15, 1295-1302	3.6	17
164	Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00098	4.2	8
163	A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019 , 24, 1174-1179	5.7	7
162	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-9	3.6	17
161	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e117-e129	3.8	32
160	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 2403-2413	12.9	29

159	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019 , 19, 80-87	3.8	11
158	A clinical trial protocol paper discussing the BRIGHTER study. <i>Future Oncology</i> , 2018 , 14, 901-906	3.6	15
157	Clinical Trials and Progress in Metastatic Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018 , 27, 349-365	2.7	38
156	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018 , 37, 3440-3455	9.2	27
155	Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 140-146	2.7	5
154	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. <i>Gut</i> , 2018 , 67, 320-332	19.2	255
153	Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. <i>Small GTPases</i> , 2018 , 9, 452-456	2.7	5
152	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018 , 23, 25-34	5.7	44
151	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. <i>Advances in Radiation Oncology</i> , 2018 , 3, 34-41	3.3	9
150	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 78-91	7	11
149	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018 , 10,	6.6	12
148	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018 , 142, 1671-1675	7.5	7
147	Cholangiocarcinoma With Genetic Aberrations: A Unique Clinical Phenotype.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-12	3.6	33
146	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 276-282	2.2	357
145	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 1063-1073	2.8	3
144	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 165-170	2.2	49
143	The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 531-534	2.7	8
142	Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 561-568	2.7	11

141	Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 569-573	2.7	29
140	Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer</i> , 2017 , 123, 1303-1312	3.1	70
139	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2017 , 18, 446-453	21.7	223
138	Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 485-498	6.4	3
137	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. <i>Cancer Research</i> , 2017 , 77, 2647-2660	10.1	60
136	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017 , 8, 14755	17.4	56
135	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017 , 5,	4.8	8
134	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. <i>Journal of Oncology Practice</i> , 2017 , 13, e62-e67	3.1	1
133	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 445-446	5.4	
132	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017 , 6, 91-100	2.1	7
131	Biliary cancer: intrahepatic cholangiocarcinoma extrahepatic cholangiocarcinoma gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 293-301	2.8	26
130	Outcomes of definitive chemoradiation in patients with esophageal cancer. <i>Ecological Management and Restoration</i> , 2017 , 30, 1-7	3	5
129	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017 , 60, 109-119	14.4	34
128	Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. <i>Pancreas</i> , 2017 , 46, 1152-1157	2.6	38
127	Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. <i>Cancer</i> , 2017 , 123, 4680-4686	6.4	25
126	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017 , 17, 262	4.8	12
125	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017 , 22, 1107-1116	5.7	66
124	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 344-356	6.1	20

123	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 489-502	12.9	32
122	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 75-82	5.4	34
121	Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. <i>Molecular Cancer Research</i> , 2017 , 15, 26-34	6.6	20
120	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 61-8	12.9	79
119	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016 , 122, 3838-3847	14.7	185
118	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016 , 12, 260-265	1	
117	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. <i>JAMA Surgery</i> , 2016 , 151, e161137	5.4	263
116	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. <i>Medical Oncology</i> , 2016 , 33, 4	3.7	1
115	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016 , 18, 863-8	8.1	24
114	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	14
113	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016 , 42, 10-7	14.4	14
112	Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e61-3	3.8	7
111	Application of next-generation sequencing in gastrointestinal and liver tumors. <i>Cancer Letters</i> , 2016 , 374, 187-91	9.9	4
110	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2565-74	12.9	52
109	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 545-557	40	630
108	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2016 ,	3.8	12
107	Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. <i>Oncotarget</i> , 2016 , 7, 5306-12	3.3	6
106	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016 , 22, 5668-77	5.6	10

105	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016 , 48, 596-604	5.2	20
104	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. <i>OncoTargets and Therapy</i> , 2016 , 9, 5931-5941	4.4	3
103	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2016 , 6, 21-30		7
102	Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. <i>Frontiers in Oncology</i> , 2016 , 6, 148	5.3	23
101	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 614-618	2.7	13
100	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1528-1534	7.3	12
99	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. <i>Neoplasia</i> , 2016 , 18, 765-774	6.4	14
98	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016 , 11, 807-814	5	2
97	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016 , 33, 48	3.7	18
96	Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2281-6	3.1	37
95	Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. <i>Cancer</i> , 2016 , 122, 3657-3666	6.4	35
94	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. <i>Scientific Reports</i> , 2015 , 5, 10867	4.9	64
93	Second-line outcomes in metastatic colorectal cancer--raising the bar for the high jump rather than the doing the limbo. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 133-43	2.2	2
92	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 727-36	7.4	37
91	Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv274	9.7	59
90	Maintenance therapy for colorectal cancer: which regimen and which patients?. <i>Drugs</i> , 2015 , 75, 1833-42	12.1	1
89	Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1153-9	3.1	184
88	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 1005-12	3.5	2

87	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 719-28; quiz 728	7.3	154
86	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. <i>Scientific Reports</i> , 2015 , 5, 12122	4.9	49
85	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). <i>Vaccines</i> , 2015 , 3, 519-43	5.3	13
84	Selumetinib for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 111-123	5.9	20
83	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , 2015 , 20, 1132-9	5.7	69
82	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 149-59	7.4	83
81	Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 362	9.7	37
80	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. <i>Oncotarget</i> , 2015 , 6, 22206-13	3.3	6
79	Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. <i>Oncotarget</i> , 2015 , 6, 44509-22	3.3	11
78	A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 336-40	2.8	2
77	CA 19-9 as a Serum Biomarker in Cancer. <i>Biomarkers in Disease</i> , 2015 , 179-201		2
76	The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. <i>Annals of Surgical Oncology</i> , 2014 , 21, 862-867	3.1	4
75	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. <i>Investigational New Drugs</i> , 2014 , 32, 113-22	4.3	37
74	Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. <i>Carcinogenesis</i> , 2014 , 35, 2203-13	4.6	34
73	Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 91, 9-34	7	24
72	Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1123-30	7.3	25
71	Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 235-43	7.3	13
70	Moving forward with expanding to an "all-RAS mutational analysis" in metastatic colorectal cancer: beyond KRAS mutations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 299-300	7.3	4

69	Colon cancer, version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1028-59	7.3	171
68	Pain, depression, and fatigue: loneliness as a longitudinal risk factor. <i>Health Psychology</i> , 2014 , 33, 948-575		173
67	Ampullary cancer: an overview. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , 112-5	7.1	41
66	Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 2186-91	3.3	8
65	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014 , 16, 553-7	8.1	70
64	Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. <i>JAMA Surgery</i> , 2014 , 149, 18-25	5.4	29
63	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014 , 120, 1780-6	6.4	22
62	CA 19-9 as a Serum Biomarker in Cancer 2014 , 1-19		
61	Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. <i>Pancreas</i> , 2014 , 43, 343-9	2.6	8
60	Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. <i>Annals of Surgery</i> , 2014 , 259, 102-8	7.8	42
59	Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. <i>Cancer</i> , 2013 , 119, 285-92	6.4	80
58	A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. <i>Cancer</i> , 2013 , 119, 2692-700	6.4	138
57	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1499-506	3.5	47
56	Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. <i>Journal of Immunology</i> , 2013 , 191, 217-27	5.3	34
55	Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. <i>Journal of the American College of Surgeons</i> , 2013 , 217, 347-57.e1	4.4	35
54	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013 , 31, 685-95	4.3	22
53	What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. <i>Surgery</i> , 2013 , 154, 1100-9	3.6	11
52	A phase II study of modulated-capecitabine and docetaxel in chemo-naïve patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2013 , 79, 27-32	5.9	4

51	A RAND/UCLA appropriateness study of the management of familial gastric cancer. <i>Annals of Surgical Oncology</i> , 2013 , 20, 533-41	3.1	11
50	RASmutations: impact on treatment outcome. <i>Colorectal Cancer</i> , 2013 , 2, 525-534	0.8	
49	FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?. <i>Oncologist</i> , 2013 , 18, 487-9	5.7	4
48	Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. <i>Cancer Research</i> , 2013 , 73, 3007-18	10.1	267
47	Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 298-307; quiz 307	7.3	15
46	Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 141-52; quiz 152	7.3	118
45	Emerging treatments in recurrent and metastatic colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11 Suppl 4, S18-27	7.3	8
44	A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. <i>Onkologie</i> , 2013 , 36, 657-60		5
43	Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 519-28	7.3	77
42	Integrating anti-EGFR therapies in metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013 , 4, 285-98	2.8	17
41	A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012 , 30, 629-38	4.3	23
40	A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, e475-81 ⁴		15
39	Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 195-9	3.8	22
38	Adjuvant Therapy Following Curative Resection of Metastases. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 217-224	1	
37	Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. <i>Medical Oncology</i> , 2012 , 29, 3101-7	3.7	17
36	Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. <i>Oncology</i> , 2012 , 83, 135-40	3.6	1
35	Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series. <i>Photomedicine and Laser Surgery</i> , 2012 , 30, 668-71		2
34	O-0002 A Phase 2 Adjuvant Trial of GI-4000 Plus Gemcitabine vs. Gemcitabine Alone in Ras+ Patients with Resected Pancreas Cancer: R1 Subgroup Analysis. <i>Annals of Oncology</i> , 2012 , 23, iv5	10.3	5

33	Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. <i>Cancer</i> , 2012 , 118, 5497-506	6.4	68
32	Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. <i>Cancer</i> , 2012 , 118, 6243-52	6.4	20
31	HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. <i>Oncology</i> , 2012 , 82, 175-9	3.6	77
30	Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012 , 18, 104-6	3.3	1
29	Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 449-54	7.3	56
28	Rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1528-64	7.3	127
27	STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 416, 246-51	3.4	94
26	Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. <i>Investigational New Drugs</i> , 2011 , 29, 347-51	4.3	16
25	A phase I study of topotecan and gemcitabine in advanced solid tumors. <i>Investigational New Drugs</i> , 2011 , 29, 1390-4	4.3	
24	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1269-79	7.4	108
23	A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 511-7	3.5	7
22	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2357-63	2.2	233
21	Colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1238-90	7.3	39
20	A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). <i>Oncologist</i> , 2010 , 15, 1310-9	5.7	56
19	Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 713-8	8.9	13
18	Gastric cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 378-409	7.3	119
17	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 319-24	3.5	4
16	A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 863-9	3.5	

15	A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 151-8	3.5	11
14	Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1019-29	3.5	18
13	A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. <i>Clinical Cancer Research</i> , 2009 , 15, 5895-901	12.9	91
12	KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 135-40	3.8	3
11	Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. <i>Anti-Cancer Drugs</i> , 2009 , 20, 444-9	2.4	50
10	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. <i>Journal of Hematology and Oncology</i> , 2008 , 1, 18	22.4	45
9	An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 895-900	7.3	7
8	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. <i>BMC Cancer</i> , 2006 , 6, 278	4.8	42
7	Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. <i>Lasers in Surgery and Medicine</i> , 2006 , 38, 881-9	3.6	29
6	Esophageal Cancer Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 328-47	7.3	24
5	Gastric Cancer Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 350-66	7.3	24
4	Hepatobiliary cancers. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 728-50	7.3	11
3	UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 310, 656-65	4.7	94
2	Late relapse of ovarian dysgerminoma: case report and literature review. <i>Gynecologic Oncology</i> , 1999 , 72, 111-2	4.9	10
1	Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42		1